CMPA ANNOUNCES KEY 2021 RESULTS AND REDUCED 2023 MEMBER FEES AT ANNUAL MEETING AND CONFERENCE

VANCOUVER, BC, Aug. 15, 2022 /CNW/ - The Canadian Medical Protective Association (CMPA) held its 2022 Annual Meeting and Conference today. The hybrid event was held both onsite in Vancouver, B.C. and online. 

During the business meeting, CMPA President Dr. Michael Cohen, and CEO Dr. Lisa Calder highlighted how the CMPA supported and advised its over 105,000 physician members, compensated patients, and improved patient safety in 2021.

The Association provided a summary of its operational achievements and presented its financial results for the 2021 fiscal year, illustrating strong financial stewardship and commitment to compensating patients, on behalf of CMPA members, who have been proven harmed by negligent medical care.

"With the impacts of COVID-19 and the current human resources crisis in healthcare, physicians continue to face significant challenges," said Dr. Calder. "We are here to support our members with medico-legal assistance and compassionate advice," continued Dr. Calder. "As the healthcare environment continues to change, we will continue to look for new ways to be there for physicians, helping them provide safe medical care to Canadian patients."

Along with its role of supporting and advising Canadian physicians, the CMPA's goal is also to prevent harm and improve the safety of medical care through evidence-based learning. In instances where there is proven harm to patients due to negligent care, the CMPA provides appropriate compensation on behalf of its physician members.

"In 2021, the CMPA paid $276 million in compensation to patients harmed by negligent medical care (fault in Québec), an increase of $70 million over the previous year, helping to support their short- and long-term care needs," said Dr. Cohen. "In fact, the CMPA paid a total of $1.2 billion in patient compensation over the last 5 years on behalf of its members."

Incoming CMPA President Dr. Jean-Hugues Brossard also addressed the meeting and discussed some of the goals he wished to achieve during his presidency. "The challenge we face during this rapid time of change is to have a good understanding of the present issues facing members, to effectively forecast what's coming in the future, and to be able to appropriately adapt and evolve," said Dr. Brossard. "I firmly believe that CMPA is positioned to meet this challenge". 

Other notable 2021 results announced at the annual meeting include:

  • Advice and support: The CMPA's 45+ physician advisors responded to over 24,000 advice calls and provided essential medico-legal support.
  • Online resources: The CMPA COVID-19 Hub, a valuable online resource for physician members, was accessed by 77% of our 105,000 members.
  • Engagement and advocacy: In 2021, the CMPA's new Strategic Engagement and Advocacy department delivered 59 submissions to regulatory authorities and engaged with governments and stakeholders, providing insights on multiple topics, including COVID-19, MAID, and virtual care.
  • Accredited learning: The CMPA's Prepped for practice: Medico-legal essentials for residents virtual symposium was delivered at 17 faculties of medicine; and accredited eLearning activities were completed more than 20,000 times.
  • Peer-reviewed research: In 2021, CMPA research manuscripts were published in the Canadian Journal of Surgery, PRS—Global Open, and the CMAJ Open. The CMPA also fulfilled 56 research project and data requests for members, sharing our data-driven insights to help physicians and stakeholder organizations.

Reduction in 2023 Membership Fees

The Association also announced its 2023 aggregate membership fees, reporting a reduction across all four CMPA fee regions.

These fee reductions reflect the CMPA's commitment to the equitable allocation of medico-legal protection costs. Each region is independent and there is no subsidization between regions (see the 2023 CMPA Fee Backgrounder for additional information on member fees).

The 2023 aggregate fees per member (which is an average, not the fee that an individual member pays) by CMPA fee region can be found below. When determining member fees, the aggregate fee for the region is calculated and used as the foundation to determine regional fees based on each member's type of work. The 2023 membership fee schedule, which provides individual member fees by region and type of work, is available on the CMPA website.

  1. British Columbia and Alberta
    The aggregate fee per member in BC and Alberta in 2023 is $1,701, down 56% from 2022 or a reduction of $60.3 million across the fee region.
  2. Ontario
    The aggregate fee per member in Ontario in 2023 is $3,198, down 45% from 2022 or a reduction of $107.8 millionacross the entire fee region.
  3. Québec
    The aggregate fee per member in Québec in 2022 is $227, down 56% from 2022 or a reduction of $5.9 millionacross the fee region.
  4. Saskatchewan, Manitoba, the Atlantic Provinces and the Territories
    The aggregate fee per member in this fee region has been set at $345 per member, down 90% from 2022, or a reduction of $41.6 million across the entire fee region.

For further information or to secure an interview, please contact: media@cmpa.org

About the CMPA

The CMPA, a not-for-profit organization, delivers efficient, high quality physician-to-physician advice and assistance in medico-legal matters, including the provision of appropriate compensation, on behalf of our members, to patients injured by negligent medical care (fault in Québec). Our evidence-based products and services enhance the safety of medical care, reducing unnecessary patient harm and healthcare costs.

As Canada's largest physician organization and with the support of our over 105,000 physician members, the CMPA collaborates, advocates, and effects positive change on important healthcare and medico-legal issues. The Association is governed by an elected Council of physicians.

SOURCE Canadian Medical Protective Association

For further information:

This information is being distributed to you by CNW Group Ltd. 88 Queens Quay West, Suite 3000 Toronto ON M5J 0B8 www.newswire.ca 
Please do not reply to this email. This is an outgoing message only. If you wish to stop receiving these types of messages from us, you can unsubscribe at any time.

Ces renseignements vous ont été distribués par le Groupe CNW Ltée. 88, Queens Quay Ouest, bureau 3000 Toronto, ON M5J 0B8 www.newswire.ca 
S'il vous plaît ne pas répondre à ce courriel. Il s'agit d'un message sortant seulement. Si vous ne souhaitez plus recevoir ce type de messages de notre part, vous pouvez vous désabonner à tout moment.

The ‘Miracle’ of the Imperial Valley: Early Treatment Protocol Saved Thousands

“How many more people would be alive today had the medical establishment followed the example of Dr. Tyson and Dr. Fareed instead of heeding arrogant bureaucrats who recommended no treatment for COVID-19 until it was often too late?” — Senator Ron Johnson, Wisconsin

Santa Ana, CA, August 11, 2022 — As the seemingly never-ending stream of COVID variants make headlines, Drs. George Fareed and Brian Tyson of the Imperial Valley in California continue to advocate for early treatment protocols.

“Our mission is to help people understand the critical importance of early COVID-19 treatment because there may be harsh surges,” the doctors say on their website (http://www.overcomingcoviddarkness.com/). “We also hope that vaccination programs recognize that COVID-19 variants will continue to arise in those who have been vaccinated as long vaccines fail to completely block the infection.”

Drs. Fareed and Tyson saw hundreds of COVID patients every day in their open-air test-and-treat center. At a time when hospitals and other medical facilities were turning away patients who weren’t “sick enough,” Drs. Fareed and Tyson turned away no one, saved thousands of lives — and were threatened with suspension of their medical licenses.

“Our results are nothing short of a miracle,” the doctors write in the introduction to their new book, Overcoming the COVID Darkness. “Despite the amazing success we achieved with more than 7,000 patients, all of the major medical organizations — from the WHO, to the NIH, to the CDC — did not welcome our information.”

In Overcoming the COVID Darkness, the doctors share their candid, deeply compelling story, and attempt to provide readers with clarity about COVID and alleviate fears. 

“People need to know — and be reassured — that we will survive this pandemic, just like pandemics of the past. There is treatment available. This treatment works when used early, and it is highly effective,” the doctors say. 

Overcoming the COVID Darkness is their story, complete with testimonials from patients and other doctors, research studies, news clippings, and most of all, the reasons why this successful treatment (which includes pharmaceutical and nutraceutical ingredients) was held back from the public.  

In a recent interview, Dr. Tyson posits, “Had we done test-and-treat centers all across the United States, we could have saved 80 percent of the population that died from COVID-19.” 

About the Authors

Dr. George Fareed graduated from Harvard Medical School with Honors and completed a medical internship at Peter Bent Brigham Hospital. He has worked at NIAID, at Harvard Medical School and at UCLA School of Medicine.

He was a founder and director of scientific planning of a biotech company, Ingene (International Genetic Engineering, Inc.). Since 1991, Dr. Fareed has worked clinically in primary medical care in the Imperial Valley of California. He has been on the frontline for early COVID-19 treatment, and has practiced the whole spectrum of COVID-19 care, treating outpatients as well as inpatients as a hospitalist. He testified on November 19, 2020, in the Senate Hearing on early COVID-19 treatment.

Dr. Brian Tyson is a board-certified family practitioner who worked as an emergency physician at Arrowhead Regional Medical center for 13 years and as a hospitalist physician for 14 years before opening his own urgent care in 2018.

Dr. Tyson was the Program Medical Director for Cogent Healthcare and Beaver Medical Group. His experience with COVID-19 has been exceptional, with over 30,000 patients evaluated, and zero deaths with early treatment.

His urgent care serves a high-risk population that includes two nursing homes, and his success was due to his aggressive early management. Due to his proven methodology, Dr. Tyson is considered a frontline COVID-19 treatment expert and has been featured on multiple media sites.

For more information, please visit www.overcomingcoviddarkness.com.

Overcoming the COVID Darkness: How Two Doctors Successfully Treated 7000 Patients

ISBN-13: 979-8985558302 (paperback)

Available from Amazon.com, Audible and iTunes

###

Ontario Panel of Family Lawyers Finds Clients
Prefer Flexibility in Divorce Proceedings 
Survey conducted by veteran lawyers shows virtual hearings can be a good solution

TORONTO, Ontario—A panel of veteran family lawyers in Ontario led by Russell Alexander say that according to a survey conducted clients prefer to have the option of virtual hearings, in contrast to a recent decision by Ontario Family Courts that in-person hearings are the presumptive standard.

A petition to ask court officials to reconsider the decision has garnered 1,500 signatures online, while a survey of 122 people who attended an online town hall discussion last week found that most wanted the option of virtual hearings as well as in-person hearings if their lawyers deemed it beneficial.

“Virtual hearings can be a great option because they are dramatically easier for clients and allow more access to attorneys, helping keep costs down and improve legal access in rural areas,” said Alexander, founder of Russell Alexander Collaborative Family Lawyers which has offices throughout Ontario. “Clients want the option of either virtual hearings or going in-person if their attorney thinks it might help.”

The ad hoc committee of lawyers opposes new requirements that holding in-person hearings in court be the default option for family law matters such as divorces, arguing that videoconferencing proved an effective and less expensive alternative for many clients during the height of the pandemic.

Many judges switched to holding routine hearings online since the pandemic started which reduced waiting time, increased access to legal help in rural areas and made divorce less stressful for clients. They became so popular that the “Zoom divorce” was written about as a trend by top media outlets, but Ontario’s top judges recently restricted them.

In last week’s one-hour discussion of the policy, Alexander; Brian Galbraith, owner, and founder of Galbraith Family Law; Lisa Gelman, founder of Gelman & Associates; and Nafisa Nazarali, senior managing associate lawyer at Russell Alexander Collaborative Family Lawyers said that virtual hearings can make family law more accessible.

“Virtual hearings have been a game-changer for how Ontario residents get divorced and settle other difficult family law issues,” added Alexander. “It would be a shame if court officials turned their backs on this important innovation now.”

To see a recording of the virtual town hall discussion, visit: https://www.youtube.com/watch?v=3KNsWHJHa4E

                                                                                                                                                         ***

Russell Alexander Collaborative Family Lawyers 
Russell Alexander Collaborative Family Lawyers is committed to practicing exclusively in the area of family law in Ontario dealing with all aspects, including separation and divorce, child custody and access, spousal support, child support, and division of family property. A team of lawyers provide guidance from start to finish, helping clients identify and understand the legal issues as well as the options and opportunities available through the transition. The firm has offices in Toronto, Concord, Markham, Whitby, Oshawa, Lindsay and Peterborough, Ontario. 

For more information, visit: 
http://www.russellalexander.com

Preparing for supply chain disruptions in the healthcare sector

Medline Canada shares insights on healthcare supplies inventory planning

MISSISSAUGA, ON, Aug. 11, 2022 /CNW/ - In March 2020, when COVID-19 was beginning to shut down Canadian society, shelves in stores across the country quickly went empty. Businesses found themselves struggling to keep up with demand.

Since then, supply chain shortages have impacted multiple sectors, including healthcare. Labour disruptions and shortages, transportation problems, a lack of raw materials and rising inflation have all intertwined to create this problem. It's led to healthcare settings like hospitals "getting creative" with their supplies. [1]

According to Roger Bourbonnais, Senior Vice President of Acute Care and Skin Health at Medline Canada, Corporation, while getting creative is one way to weather problems in the supply chain, setting up a smart system is most effective in tackling the issue. Bourbonnais offers these planning considerations to help healthcare providers better prepare for supply chain impacts:

Take control of how you buy
Supply costs are one of the most significant expenses for healthcare facilities. Consolidating to a single vendor is a proven way to lower costs. During this process, you could also consider product standardization to optimize quality-price value and improve practice consistency with a customized formulary focused on clinical outcomes over brand name.

Ensure you have good data
When you have a better handle on your data, you can better understand what's happening in your supply chain. Fifty-six percent of CEOs say they are concerned about the integrity of the data they use for decision-making. [2] Collecting data and keeping it organized is vital. Equally as important is maintaining your datasets. This includes data cleansing, going through and ensuring everything is up to date and accurate.

Leverage your data
A lot of work goes into negotiating supply contracts and savings. Don't let this hard work go to waste. Ensuring clinical staff order from those formularies and that you're getting the contracted price is crucial. Additionally, building out software infrastructure so there's real-time visibility into spend is another critical step to ensure you're optimally using your data. 

Automating your processes
Over and understocking, supply hoarding, expired products and labour-intensive manual restocking processes quickly drive-up operating expenses. By leveraging automated systems for inventory management, you have an opportunity to improve costs and simplify workflow. This could mean tracking and managing inventory to all care points within your system using a comprehensive technology-powered platform.

Tackling supply chain issues in healthcare can't be a solo effort – leverage your supply partners to help you optimize foundational supply chain logistics, deliver operational excellence and strategically prepare for whatever supply chain impact happens next – whenever it happens.

[1] https://www.cbc.ca/news/canada/ottawa/ottawa-hospitals-shortages-.6253957#:~:text=18-,As%20Canadian%20hospitals%20continue%20to%20struggle%20to%20catch%20up%20on,care%20has%20not%20been%20spared.
[2] https://home.kpmg/xx/en/home/insights/2017/08/trusted-analytics-matter-to-ceos.html

Medline Canada, Corporation
Medline is a leading global manufacturer and provider of high-quality medical products and services to the healthcare industry. Our expertise in healthcare solutions throughout the continuum of care, coupled with the scale and agility of our supply chain, allows us to partner with our customers to enhance patient care, improve clinical outcomes, drive effective cost management and provide fast access to quality products. 

By applying our CARES values every day, in all that we do, Medline Canada is deeply committed to the health and wellbeing of our customers, employees, partners and communities. With more than 550 employees, including 125 dedicated sales and clinical professionals, and eight distribution centres located across Canada, we are a trusted partner in delivering the healthcare needs of Canadians from coast-to-coast – Together Improving Care™. For more information, visit: www.medline.ca

SOURCE Medline Canada, Corporation





https://www.youtube.com/watch?v=7oyvHPILxxw

I am back on YouTube! Please subscribe! Like! And Comment!

www.youtube.com/trainitright

Good Morning TIR Fam! I hope that your week is off to a great start! Mine is!

I am so sorry that I have been so MIA! Trying to get my mojo back for getting content out. Truth be told I have been in a funk! We all have those times. I am not superhuman dispite what some people thing! The difference for me is that I always stay committed to my goals even when I am not feeling motivated. That's called discipline. And although some days I haven't felt like doing cardio or training I still get up and put my best foot forward.

As you know I have also been in an extended off seasons. But it has been for a purpose. To build up my metabolism, do. some body recomposes and just find myself again. This was necessary. And the stage will always be there. But also truth be told off season is boring and I felt like I didnt have that much to share. So I didnt share as much about fitness, training or nutrition as I usually do. However I am going to make more of an effort to start sharing again! So thanks for sticking with me during these times!


Interested in supporting me?

Order Ballistic Supplements and use code: TRAINITRIGHT at check out to save!



Need help with training, nutrition and supplementation?

I can help! I now have client spots open....

SERIOUS INQUIRES ONLY.

I have helped hundreds of men and women achieve their goals not just for stage but through transformation/lifestyle coaching.

For anyone interested in coaching - I have limited spots available for prep, off-season and transformation left. So if you are serious about your goals.Contact me NOWorSign Up HEREI also do ONLINE POSING for:
BIKINI
FIGURE
WELLNESS
MENS PHYSIQUEContact me NOWNot interested in coaching but still want to support me and my sport....click HERE Thanks so much!

The ancient healing properties of crystals are a relatively untapped phenomena of the natural world. The Earth is composed of thousands of minerals with specific and potent abilities to heal, balance and fortify our existence. Their vibrational patterning receives, transmits and amplifies energy and can be found in countless areas of modern and innovative technology from cars to clocks to communications equipment. These rich treasures of the natural world can foster harmonious energy to our homes, workplaces, and personal health and wellbeing. 

Placing crystals in your home, specifically, in places where you sleep, work, and relax, offers a safe and natural way to promote positive energy flow while removing negative energies brought about by stress, sadness, or sickness. 

Follow the guide below to unlock crystal alchemy’s most potent cures:

1. Frequency

Crystals absorb movement and pressure from the environment and transform it into a type of energy that carries a certain frequency. This frequency depends on an individual crystal’s constitution. However, each crystal produces a unique frequency that has been found to provide individuals with feelings of relief, joy, and gratitude. Although considered a pseudoscience by the scientific community, studies such as the one conducted by the brothers Pierre and Jack Curie in 1880, found that applying pressure, such as achieved by holding a crystal, could produce an electric current. This same electric current has been found by many to be a source of comfort and energy in times of need.

2. Mentality

With the existence of so many competing theories regarding the efficacy of crystal alchemy, one consensus appears on both sides of the argument: The power of the mind is immutable. While the electrical current produced by holding a crystal is seen by many as insufficient to achieve emotional change within an individual, the belief that the energy is achieving change has shown positive results. Many argue that using a crystal as a focal point for one’s intentions can produce a change in the body’s chemistry, bringing its frequency to par with the frequencies associated with gratitude and happiness. 

3. How to Use

Crystals can be used in a variety of ways to augment your mentality. Some ways include placing a crystal like moonstone or selenite beneath your pillow to induce fitful sleep, you can hang a pyrite crystal around your neck to provide energy to you throughout the day, or you can hold a crystal such as rose quartz when meditating to create feelings of love and contentment. Below is an example I do on a regular basis: 

Choose your crystal: What feeling are you looking for? Relief? Love? Gratitude? Each crystal has a unique frequency geared towards producing a strong emotion. Take a look at the crystals offered on my site: …  

Cleanse your crystal: To achieve the best results, you have to remove the previous energies in the crystal before use. These energies are often residual, appearing after each meditation. To cleanse it, run it under cold water for 10 minutes, or charge with an hour of midday sun after rinsing in cool water. 

4. Set your intention

Choose a focus that you will channel into your crystal. It can be something like “I release all that no longer serves me” or “I receive the strength and courage to live to my potential”. 

Begin Meditating: Now it's time to begin the process of centering yourself. First, relax your breathing, taking in slow deep breaths. Second, as you begin to relax, imagine drawing in the energy produced by your chosen crystal. Visualize it flowing throughout your body, filling each cell with boundless energy. Lastly, as you begin to feel cocooned in the crystal’s energy, imagine your intention becoming reality with the help of the crystal's energy. Once you have achieved this balance, you may slowly open your eyes, making sure to breathe slowly and deeply to retain your peaceful state. After giving yourself some time to reflect on what you experienced, allow yourself to feel grateful for this expansion of new energy and intention. It is the first step on the wondrous journey of cultivating inner harmony. 


W

Lynparza receives Health Canada approval as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

First and only approved medicine targeting germline BRCA mutations in high-risk early breast cancer

MISSISSAUGA, ON, Aug. 11, 2022 /CNW/ - Health Canada has granted a Notice of Compliance with Conditions (NOC/c) for Lynparza® (olaparib) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.1 Patients must have confirmation of a germline BRCA mutation before Lynparza treatment is initiated.1

This approval was granted under Health Canada's accelerated review pathway and based on results from the OlympiA Phase III trial,1 presented during the 2021 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. The OlympiA trial demonstrated a reduction in the risk of invasive breast cancer recurrences, second cancers or death by 42 per cent versus placebo (based on a hazard ratio [HR] of 0.58; 95% confidence interval [CI] 0.41-0.82; p<0.0001).1 

"Although most HER2-negative early breast cancers now have excellent outcomes, the risk of disease recurrence for persons with high-risk breast cancers and BRCA mutations remains unacceptably high, with a significant potential to advance to advanced disease, where a cure is no longer an option," said Dr. Karen Gelmon, Professor of Medicine, University of British Columbia and Medical Oncologist, BC Cancer. "Today's approval of olaparib is an important step forward, offering these patients a much-needed option that can improve survival for persons with high-risk early breast cancer. It also stresses the importance of BRCA testing as soon as possible after diagnosis to identify eligible patients."

In Canada, it is estimated that 94 per cent of all breast cancers are detected at an early stage.2 Despite advances in the treatment of early breast cancer, up to 30 per cent of patients with high-risk clinical and/or pathologic features recur within the first few years.3 The risk is particularly high for patients with germline BRCA mutations, who are more likely to be diagnosed at a younger age than those without these mutations.2

"This approval is fantastic news for the many women with high-risk early breast cancer who live with the ongoing fear of recurrence and what that means for their future," said Cathy Ammendolea, Chair of the Board, Canadian Breast Cancer Network. "New treatment options can provide hope for patients and their families, and we look forward to Canadian women having access to this treatment."

"Hereditary breast cancer is often diagnosed at a younger age and Rethink has supported and advocated for young people with breast cancer for more than 20 years. Facing their mortality at a young age, they want what all cancer patients want – care that will lead to the best possible outcome, including reducing their future cancer risk," said MJ DeCoteau, Founder and Executive Director of Rethink Breast Cancer. "They want to survive, and eventually thrive, and now patients with a BRCA-mutated breast cancer will have a treatment that is shown to help them do just that."

About the OlympiA Phase III Trial 

OlympiA is a Phase III, double-blind, placebo-controlled, multicentre trial testing the efficacy and safety of Lynparza as adjuvant treatment in patients with gBRCAm HER2-negative high-risk early breast cancer, who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.1 The primary endpoint was invasive disease-free survival (iDFS), and key secondary outcome measures include distant disease-free survival (DDFS) and overall survival (OS).1

In the key secondary endpoint, results showed an improvement of distant disease-free survival (DDFS) in the intention to treat (ITT) population, where Lynparza reduced the risk of distant disease recurrence or death by 43 per cent (based on a HR of 0.57 (99.5% CI:0.39-0.83; P < 0.001).1 Interim overall survival (8% maturity, DCO 27 March 2020) did not meet statistical significance.1 

The safety and tolerability profile of Lynparza in this trial was in line with that observed in prior clinical trials.1 

About the BRCA Gene 

BRCA1 and BRCA2 are human genes that produce proteins responsible for repairing damaged DNA and play an important role maintaining the genetic stability of cells.4

When either of these genes is mutated or altered such that its protein product either is not made or does not function correctly, DNA damage may not be repaired properly, and cells become unstable. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer and confer sensitivity to PARP inhibitors including Lynparza.5

About Lynparza (olaparib)

Lynparza was the first oral (PARP) inhibitor approved in Canada. Lynparza exploits tumour DNA damage response (DDR) in cells/tumours harbouring a deficiency in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2, to selectively kill cancer cells.1 Lynparza is the only PARP inhibitor currently approved in multiple tumour types in Canada including breast, ovarian, pancreatic and prostate cancers.

Lynparza has been issued conditional marketing authorization for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy pending the results of studies to verify its clinical benefit. Patients should be advised of this conditional marketing authorization.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism (CVRM), and Respiratory & Immunology. The company employs more than 1,200 people across Canada, including 700 employees at our head office and clinical research hub in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.  

REFERENCES 

1 Lynparza Product Monograph, July 27, 2022.

2 S, Masoud H, Weir HK, et al. Cancer in Canada: Stage at diagnosis. (1209-1367 (Electronic).

3 Colleoni M, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016 Mar 20; 34(9):927-935.

4 Canadian Breast Cancer Network, BRCA Gene Mutations. Available at: https://cancer.ca/en/cancer-information/cancer-types/breast/risks#ci_BRCA_gene_mutations_10_185_04. Accessed July 12, 2022.

5 Roy R, et al. BRCA1 and BRCA2: Different Roles in a Common Pathway of Genome Protection. Nat Rev Cancer. 2016;12(1):68-78.

SOURCE AstraZeneca Canada Inc.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution 

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/9kD5b

In its 2021 industry report, ReportLinker estimated the global anti-hypertensive drugs market at $24.17 billion in 2020 on its way to reach $27.81 billion in 2025. All told, hypertension costs the country on average $131 billion annually, and even more sobering, in 2020 alone, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.

A recognized global innovator in drug-delivery platforms, Lexaria Bioscience Corp. (NASDAQ: LEXX) is determined to fill the need for a safe, effective, tolerable treatment for hypertension and have a meaningful impact on comorbidity-related costs and deaths. Its patented flagship product, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive, and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing. 

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by up to five to ten times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the innovative tech is also being evaluated for orally administered anti-viral drugs, nonsteroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and more than 50 patents pending worldwide. 

For more information about the company, please visit www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX 

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

New Data Suggests a Gap in Access to Care for Ontarians Living with a Chronic Illness

TORONTO, Aug. 11, 2022 /CNW/ -  Incidents of chronic disease have been steadily increasing in Canada for many years, most recently compounded by the COVID-19 pandemic which created a substantial backlog. It is estimated that there are 2.6 million Ontarians living with unmanaged chronic conditions that had difficulty obtaining care. However, new data also suggests pharmacists are in a unique position to help effectively manage diabetes, cholesterol and hypertension in patients.  

As part of a recent pilot at 53 Shoppers Drug Mart locations in Ontario and British Columbia, pharmacists have administered over 15,000 point of care tests on more than 6,900 patients to date, including those with risk for chronic conditions such as diabetes and heart disease and those determined to be at high risk of having a heart attack in the next 10 years. The pilot found that almost 60 per cent of patients needed an intervention to better manage their chronic disease. For example, based on the point of care test results, the pharmacist may have adjusted the dose of an existing medication or may have contacted the patient's primary care provider to request a new prescription. On average, 31 percent received a new chronic medication, 28 percent required a change in their current medication, and 235 patients were newly identified as diabetic. Research has also shown that pharmacist-led care management resulted in lower total cost of care and fewer hospitalizations. These results demonstrate the important role that a pharmacist plays as a key member of the patient's health care team.

"This pilot highlights the significant gap in access to treatment for those living with a chronic illness in Ontario," said Justin Bates, Chief Executive Officer of the Ontario Pharmacists Association. "However, this pilot project also demonstrates that pharmacists can play a role in helping to close this critical healthcare gap by offering accessible, high-quality care."

Pharmacy professionals played a critical role in ensuring access to care for Ontarians through COVID-19. As we turn our attention to the growing waitlists for care following the pandemic, there is further opportunity to leverage Ontario's pharmacy professionals to improve timely access to care and increase health system capacity. Through medication reviews, access to point of care testing, and soon to come minor ailment services, pharmacists can better support Ontarians by providing timely access to care and support for the management of both acute and chronic diseases.

ABOUT OPA

The Ontario Pharmacists Association is committed to evolving the pharmacy profession and advocating for excellence in practice and patient care. With more than 10,000 members, OPA is Canada's largest advocacy organization, professional development and drug information provider for pharmacy professionals across Ontario. By leveraging the unique expertise of pharmacy professionals, enabling them to practice to their fullest potential, and making them more accessible to patients, OPA is working to improve the efficiency and effectiveness of the healthcare system. The pharmacy sector plays a strong role in Ontario with an economic impact of more than $6.3 billion across 4,600 pharmacies, employing 60,000 Ontarians. For more information on OPA, visit https://www.opatoday.com.

Related Links:

http://www.opatoday.com

SOURCE Ontario Pharmacists Association

Samsung Leads Holistic Health Innovation with the launch of Galaxy Watch5 and Galaxy Watch5 Pro

New Galaxy Watch5 Series is packed with insightful sleep tracking, personalized design and enhanced durability to shape everyday health and wellness habits

MISSISSAUGA, Ontario, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Samsung Electronics Canada today announced the Galaxy Watch5 and Galaxy Watch5 Pro, shaping fitness and wellness habits with intuitive insights, advanced features, and powerful capabilities. The newest addition to the Galaxy Watch lineup, the Galaxy Watch5 Pro is the most durable and feature-packed watch yet by Samsung, designed to meet the rigorous demands of the most active users and outdoor enthusiasts. The Galaxy Watch5 enhances features that consumers rely on every day with a customizable iconic design. This new series represents the culmination of Samsung’s wellness vision and leadership in advanced fitness capabilities, redefining digital health and wellness for users.

“We’re dedicated to giving our Galaxy Watch community the tools, data and resources needed to not only understand their overall health and wellness better, but to coach them on their journey,” said Dr. TM Roh, President and Head of Mobile eXperience Business at Samsung Electronics.

Cutting-edge Sensor Technology to Better Understand You
With a growing desire to ensure people can act on individual wellness goals and access fitness and wellness features, Samsung has set out to provide in-depth tracking and practical data offering users deeper insights that help guide them towards their wellness goals. Galaxy Watch5 is equipped with a unique BioActiveSensor technology from Samsung that drives the next era of digital health. First introduced on the Galaxy Watch4 Series, the BioActive Sensor uses a single unique chip that combines three powerful health sensors – Optical Heart Rate (PPG)1Electrical Heart Signal (ECG)2 and Bioelectrical Impedance Analysis(BIA)3 – to deliver extensive readings that include heart rate, blood oxygen level, and even stress level4driving the next era of digital health. In addition, users can get a deeper understanding of their heart by tracking blood pressure5 and ECG6 – right from their wrist7.

With an increased surface area and more direct contact with your wrist, the Galaxy Watch5 tracks fitness and wellness metrics now with greater accuracy than the Galaxy Watch4.

Developed in partnership with GoogleWear OS Powered by Samsung offers Galaxy Watch5 users a more connected and intuitive experience through seamlessly connected wearables designed to help achieve more for any lifestyle.

Holistic Insights to Enhance Everyone’s Wellness Journey
Designed for everyday wins, the Galaxy Watch5 offers a comprehensive end-to-end experience that goes beyond fitness activities and into the post-workout, rest, and recovery process. The Body Compositionmeasurement tool8 provides a complete snapshot of the user’s overall wellness, providing them with a tailored approach to set goals, guide them through personalized workouts and track progress. And when it’s time to rest, the Galaxy Watch5 Series empowers users with recovery data, including post-cardio heart rate after an intense workout9, and customized recommendations on water consumption based on sweat loss10.

A good night’s rest is important in wellness, and that’s why Samsung is helping users have a better night’s sleep11. Understand sleep patterns through Sleep Scores that monitor the different stages of sleep, together with snore detection12 and blood oxygen levels. Achieve improved sleep habits with advanced Sleep Coaching13 that gives a tailored month-long guided program. Users can sleep soundly, knowing that the enhanced fall detection feature is designed to notify an emergency contact if you or your loved one stumbles at home or falls out of bed14.

No need to worry that your watch may run out of power or get damaged in rough terrain; the Galaxy Watch5 comes with a 13% larger battery than its predecessor15 and provides eight hours of sleep tracking with just eight minutes of charging, which is 30% faster than the Galaxy Watch4. An extra layer of durability protects the Galaxy Watch5, and includes the first smartwatch display from Samsung featuring a Sapphire Crystal, which offers a harder outer layer16, so your watch is fit for day-to-day use. Cue up your favourite song on Spotify with just your voice using Google Assistant. Coming soon, find your way using Google Maps from your wrist17 without a smartphone connection18. Music and audio lovers will appreciate updates that include new apps like SoundCloud and Deezer19. Additionally, One UI Watch 4.5 offers a better typing experience, an easier way to make calls, and a host of new accessibility features to make the Galaxy Watch more intuitive.

Galaxy Watch5 Pro, More Features and Greater Durability for the Outdoor Enthusiast
Created for those that love the great outdoors, the Galaxy Watch5 Pro is the newest addition to the Galaxy Watch portfolio. From hiking to cycling and beyond, the Galaxy Watch5 Pro is ready for the challenge thanks to the premium materials used. The enhanced Sapphire Crystal better resists any wear and tear20 and a durable titanium casing protects the display with a protruded bezel design. The Galaxy Watch5 Pro also comes with an all-new D-Buckle Sport Band21 that offers rugged durability with a sleek and clean fit.

Built strong, the Galaxy Watch5 Pro has the largest battery in a Galaxy Watch yet. It’s 60% larger than the Galaxy Watch4, which is key to keeping up with you while you conquer a new route. Take advantage of GPX, that’s available for the first time on a Galaxy Watch. Head out on a hike and record and share it with fellow trail-lovers on the Samsung Health app22 with Route Workout. You can also download hiking and cycling routes as you practice for your next race or look to mix up your routine. As you hike or cycle, keep your eyes on the path and away from the map with intuitive Turn-by-Turn directions23. When you’re ready to head home, the Galaxy Watch5 Pro will get you there easily with the Track back feature that takes you back the way you came24.

Canadian Pricing and Availability25 
The Galaxy Watch5 and Galaxy Watch5 Pro are available for pre-order starting on August 10, 2022 and for purchase starting August 26, 2022 at samsung.com/ca, Samsung Experience Stores and with major carrier and retail partner locations across Canada.

The Galaxy Watch5 offers a modern and minimalist design, and features that help you achieve more every day. It comes with all-new neutral colour options that will turn heads, with the Large 44mm option available in Graphite, Sapphire, and Silver and the Small 40mm option available in Graphite, Pink Gold, and Silver, which features a Bora Purple strap that pairs perfectly with the Galaxy Z Flip4. The Galaxy Watch5 will start at $349 (MSRP) for the Bluetooth version and $419 (MSRP) for the LTE version.

For adventure seekers looking for durability, performance and style, the Galaxy Watch5 Pro is for you. It will be available in Black Titanium and Gray Titanium, with a 45mm display, starting at $559 (MSRP) for the Bluetooth version and $629 (MSRP) for the LTE version.

Design your own watch by selecting the model, size, case colour and strap for up to 1,032 unique combinations in the Galaxy Watch5 Bespoke Studio on Samsung.com26. Now, users can build a watch that’s unique to them. With a greater selection of straps and faces, they can mix and match to express their personal style with the new Sport Band.

To learn more about the Galaxy Watch5 and Galaxy Watch5 Pro, please visit: 
Galaxy Watch5 Bespoke: https://www.samsung.com/ca/mobile/galaxy-bespoke/galaxy-watch5/

Promotional Offers
Canadians can enjoy a bonus Wireless Charger Pad Duo27 when they pre-order a Galaxy Watch5 Series smartwatch and complete their purchase between August 10 and August 25, 2022.

Trade-In and trade up
Canadians can also get up to a $100 credit (plus a credit for the trade-in value of their eligible old smartwatch) when they pre-order a new Galaxy Watch5 Series device between August 10 and August 25, 2022 (upon completion of purchase), or purchase an eligible Galaxy Watch5 Series device28 between August 26 and October 3, 2022.

Peace of Mind with Samsung Care+
With a Samsung Care+ Plan, Canadians can experience a total care service for their new Galaxy Smartphone, Laptop, Tablet or Wearable device. You’ll be protected for up to two years against physical or liquid damage and mechanical malfunction or defects, with a team of dedicated Galaxy experts available to help you get back on track.29

For more information about the latest Samsung Galaxy devices including specifications: www.samsung.com/ca/

About Samsung Electronics Canada Inc. 
Samsung Electronics Canada inspires Canadians to reach their full potential through a transformative ecosystem of products and services that deliver innovation and distinct design to every aspect of their connected lives. The company is redefining the worlds of TVs, smartphones and wearable devices, tablets and digital appliances. In 2022, Samsung was ranked as one of Canada’s “Most Reputable Companies” in Léger’s Corporate Reputation Study. Dedicated to helping make a difference in the lives of Canadians, Samsung’s award-winning corporate giving initiatives support public education and health-related issues in communities across the country. To discover more, please visit. 

Follow Samsung Canada at facebook.com/SamsungCanada, or Instagram @samsungcanada or Twitter @SamsungCanada. 

Contact:
Aneesha Singh
North Strategic
Tel: 416-988-8598  
aneesha.singh@northstrategic.com

Device Specifications30 31

Galaxy Watch5Galaxy Watch5 Pro
Material &
Colour
Armor Aluminum case with Sport Band
- 44mm: Graphite, Sapphire, Sliver 
- 40mm: Graphite, Pink Gold, Sliver
Titanium case with D-Buckle Sport Band
- Black Titanium, Gray Titanium
Dimensions32
& Weight33
- 44mm: 43.3 x 44.4 x 9.8 mm, 33.5g
- 40mm: 39.3 x 40.4 x 9.8 mm, 28.7g
45.4 x 45.4 x 10.5 mm, 46.5g
DisplaySapphire Crystal 
- 44mm: 1.4" (34.6mm) 450x450 Super AMOLED, Full Colour Always On Display
- 40mm: 1.2" (30.4mm) 396x396 Super AMOLED, Full Colour Always On Display
Sapphire Crystal 
- 1.4" (34.6mm) 450x450 Super AMOLED, Full Colour Always On Display
ProcessorExynos W920 Dual-Core 1.18GHz
Memory1.5GB RAM + 16GB internal storage
Battery
(typical)
34
- 44mm: 410mAh
- 40mm: 284mAh
590mAh
ChargingFast Charging (WPC-based wireless charging)
OSWear OS Powered by Samsung (Wear OS 3.5)35
UIOne UI Watch4.5
SensorsSamsung BioActive Sensor (Optical Heart Rate + Electrical Heart Signal + Bioelectrical Impedance Analysis), Temperature Sensor, Accelerometer, Barometer, Gyro Sensor, Geomagnetic Sensor, Light Sensor
ConnectivityLTE36, Bluetooth 5.2, Wi-Fi 802.11 a/b/g/n 2.4+5GHz, NFC, GPS/Glonass/Beidou/Galileo
Durability375ATM + IP68 / MIL-STD-810H
CompatibilityAndroid 8.0 or higher and with more than 1.5GB of RAM38

1 The heart rate software functions are not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease. Requires Galaxy smartphone with Android 8.0 or later, 1.5GB RAM or more and the latest version of the Samsung Health Monitor app (available only at the Samsung Galaxy Store).
2 The heart rate software functions are not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease. Requires Galaxy smartphone with Android 8.0 or later, 1.5GB RAM or more and the latest version of the Samsung Health Monitor app (available only at the Samsung Galaxy Store).
3 The Samsung BIA is a body analyzer that uses bioelectrical impedance analysis (BIA) technology to track body composition based on weight, body fat, body mass index (BMI), skeletal muscle, body water, and basal metabolic rate (BMR) measurements. The Samsung BIA measurement is to be used for fitness and wellness only and is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease. Please consult with a medical professional for any specific condition.
4 These features are intended for general wellness and fitness purposes only. Not intended for use in detection, diagnosis, or treatment of any medical condition or disease. Availability of these features may vary by market or device. Requires Galaxy smartphone with Android 8.0 or later, 1.5GB RAM or more and the latest version of the Samsung Health app (version 6.22 or later).
5 Blood pressure feature only to be used by adults 22 years and older. Intended for general wellness and fitness purposes only. Not intended for use in detection, monitoring, diagnosis, treatment of any medical condition or disease. The measurements are for your personal reference only. Please consult a medical professional for advice. For accurate BP readings, a calibration is required every 4 weeks by BP monitor &arm cuff.
6 Intended to create, record, store, transfer, and display a single channel electrocardiogram (ECG), similar to a Lead I ECG for adults 22 years and older. The ECG feature is not intended to replace traditional methods of diagnosis or treatment. The ECG feature is not intended for users with other known arrhythmias. If an irregular heartbeat or atrial fibrillation is detected, consult a doctor. If you experience symptoms of a heart attack, stroke, or other cardiovascular conditions, do not rely on the notification of the device and consult a doctor. Follow the instructions for use. If symptoms persist, worsen or change unexpectedly, talk to your health professional.
7 The blood pressure and electrocardiogram measurements are only functional with a compatible Samsung device that has the Samsung Health Monitor app installed and Galaxy Watch5 Series devices with the Samsung Health Monitor app installed. Service may be restricted when users travel to non-service countries. Check out https://www.samsung.com/ca/apps/samsung-health-monitor/ for more information and latest update on service markets.
8 The Samsung BIA is a body analyzer that uses bioelectrical impedance analysis (BIA) technology to track body composition based on weight, body fat, body mass index (BMI), skeletal muscle, body water, and basal metabolic rate (BMR) measurements. The Samsung BIA measurement is to be used for fitness and wellness only and is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease. Please consult with a medical professional for any specific condition. Any health-related information accessed through the device and/or application should not be treated as medical advice. Do not measure your body composition if you have an implanted pacemaker or other implanted medical devices. Do not measure your body composition if you are pregnant. Measurement results may not be accurate if you are under 20 years old.
9 To measure, select your exercise before you start to workout.
10 To measure, select ‘Running’ on your watch and run at least 5km/h for at least 2.5km. Only for use with outdoor running.
11 Sleep features are intended for general wellness and fitness purposes only. Not intended for use in detection, diagnosis, treatment of any medical condition or sleep disorder. The measurements are for your personal reference only. Please consult a medical professional for advice.
12 To record your snoring, wear your watch while you sleep and place your phone on a stable surface near your head, such as a nightstand, with the bottom of the phone pointed toward you.
13 For sleep pattern results, user must wear watch while they sleep for at least 7 nights and complete a survey.
14 To notify an emergency contact, a network connection is required. GPS accuracy may be affected by obstructions to the satellite signal, such as buildings.
15 Compared to Galaxy Watch4.
16 When compared to Galaxy Watch4. Based on Vickers hardness measured with constant load of 200gf.
17 A network connection is required.
18 App availability may vary by market, operator or device. Subscription fees may apply for some apps.
19 App availability may vary by market, operator or device. Subscription fees may apply for some apps.
20 When compared to Galaxy Watch4. Based on Vickers hardness measured with constant load of 200gf.
21 Do not store your device and the band near magnetic fields. Magnetic stripe cards, including credit cards, phone cards, passbooks, and boarding passes, may be damaged by magnetic fields.
22 A Galaxy Watch and Samsung Galaxy smartphone are required to use Samsung Health Monitor app. Supported watches: Galaxy Watch4, Galaxy Watch4 Classic, Galaxy Watch5, and Galaxy Watch5 Pro. Supported smartphones: Samsung Galaxy smartphone with Android 7.0 OS version or higher.
23 Provided when GPX format route file is imported for hiking and cycling and route is set as target under Samsung Health settings. Works with Bluetooth when connected via a Galaxy device.
24 This feature must be enabled for hiking or cycling under Samsung Health settings. Works with Bluetooth when connected via a Galaxy device.
25Supported models, colours, sizes and straps may vary depending on market or carrier.
26 The number of combinations available may vary depending on the country or region in which the Galaxy Watch Design Studio is available.
27 Some conditions apply. Offer available exclusively online at Samsung.com/ca and Samsung Experience Stores in Canada. See Samsung.com/ca for more details.
28 Certain conditions apply. See Samsung.com/ca for more details.
29 Terms and Conditions apply. For full Terms and Conditions, please see https://support-ca.samsung.com/secaew/consumer/ca/terms
30 Availability may vary depending on market, model and the paired smartphone.
31 All functionality, features, specifications and other product information provided in this document including, but not limited to, the benefits, design, pricing, components, performance, availability, and capabilities of the product are subject to change without notice.
32 Measured without health sensors.
33 Measured without strap.
34 Actual battery life may vary depending on network environment, usage patterns and other factors.
35 Wear OS Powered by Samsung works with phones running the latest version of Android (excluding Go edition and phones without Google Play Store). Supported features may vary between platforms and markets with compatibility subject to change.
36 LTE connectivity only available in LTE models.
37 Galaxy Watch5 Series is rated as IP68. Based on test conditions for submersion in up to 1.5 meters of freshwater for up to 30 minutes.
38 Device activation is only available after connecting to a smartphone that supports Google Mobile Services. Compatible devices may vary by market, operator or device brand.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5f741240-4169-4fbd-bdba-69e9b07d801d